Recombinant factor VIIa: new insights into the mechanism of action through product innovation.

• Tác giả: Giancarlo Castaman, Miguel A Escobar, Cedric Hermans, Maureane Hoffman, Johnny Mahlangu, Johannes Oldenburg, Charles L Percy, Steven W Pipe, Mark T Reding, Amy D Shapiro
• Ngôn ngữ: eng
• Ký hiệu phân loại: 181.112 Confucian philosophy
• Thông tin xuất bản: United States : Research and practice in thrombosis and haemostasis , 2025
• Bộ sưu tập: NCBI
• ID: 673534

Tóm tắt

Management of bleeding in persons with hemophilia and inhibitors involves treatment with bypassing agents, including recombinant activated factor VII (rFVIIa). Two rFVIIa products are commercially approved for use in the United States and the European Union. Eptacog alfa and eptacog beta share the same amino acid sequence but differ in posttranslational modifications. Although rFVIIa has been used to manage bleeding in persons with hemophilia and inhibitors for over 30 years, its mechanisms of action is still being studied.